Abstract: The invention concerns compounds of formula (I): Wherein X, R1, R2, R3 and R4 are as described herein. The invention also concerns a method for preparing same and the therapeutic use thereof.
Type:
Grant
Filed:
May 22, 2008
Date of Patent:
August 24, 2010
Assignee:
Sanofi-Aventis
Inventors:
Francis Barth, Murielle Rinaldi-Carmona
Abstract: The present invention comprises peridinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase (FAAH) enzyme inhibitors. These derivatives exert various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors. By inhibiting the metabolic activity of the FAAH enzyme, compounds often responsible for the onset of a large variety of diseases and other pathological conditions are not generated and the incidence of the disease is greatly reduced.
Type:
Grant
Filed:
August 21, 2006
Date of Patent:
August 24, 2010
Assignee:
Sanofi-Aventis
Inventors:
Ahmed Abouabdellah, Antonio Almario Garcia, Christian Hoornaert, Jean Jeunesse
Abstract: A compound corresponding to general formula (I): in which R1 represents a phenyl or naphthalenyl group optionally substituted with one or more halogen atoms or hydroxyl, cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy, (C3-C6)cycloalkyl-O— or (C3-C6)cycloalkyl(C1-C3)alkoxy groups; R2 represents either a group of general formula CHR3CONHR4 in which R3 represents a hydrogen atom or a methyl group and R4 represents a hydrogen atom or a (C1-C3)alkyl, (C3-C5)cycloalkyl or (pyridin-4-yl)methyl group; or a 2,2,2-trifluoroethyl group; or an (imidazol-2-yl)methyl group; or a (benzimidazol-2-yl)methyl group; or a phenyl group optionally substituted with one or more halogen atoms or cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl or trifluoromethoxy groups; and n represents a number ranging from 1 to 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate.
Type:
Grant
Filed:
July 28, 2009
Date of Patent:
August 17, 2010
Assignee:
Sanofi-Aventis
Inventors:
Ahmed Abouabdellah, Michele Bas, Gihad Dargazanli, Christian Hoornaert, Adrien Tak Li, Florence Medaisko
Abstract: A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I, wherein, R, R1, R2, R3 and X are as defined herein.
Type:
Grant
Filed:
December 6, 2006
Date of Patent:
August 17, 2010
Assignee:
Aventis Pharmaceuticals Inc.
Inventors:
Raymond W. Kosley, Jr., Bruce Baron, Patrick Jimonet, John G. Jurcak, Stephen J. Shimshock, Xu-Yang Zhao, Rosy Sher, Paul J. Mueller, Jennifer Beall, Matthieu Barrague, Joseph W. Guiles
Abstract: The invention concerns compounds of general formula (I), wherein n, the pyrrolopyridine ring, X, Z1, Z2, Z3, Z4, Z5 and W are as defined herein. The invention also concerns a method for preparing said compounds and their therapeutic use.
Type:
Grant
Filed:
January 8, 2008
Date of Patent:
July 27, 2010
Assignee:
Sanofi-Aventis
Inventors:
Laurent Dubois, Yannick Evanno, Andre Malanda
Abstract: This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: Wherein R, R?, R1 to R10, A, D, E, G, L and p are as defined herein. The invention also relates to processes for preparing them, pharmaceutical compositions comprising them and their therapeutic use. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.
Type:
Grant
Filed:
February 5, 2009
Date of Patent:
July 20, 2010
Assignee:
Sanofi-Aventis
Inventors:
Gerhard Jaehne, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Irvin Winkler
Abstract: Compounds of formula (I) as defined herein: inhibit the formation of the ?-amyloid peptide (?-A4) and are, therefore, useful in the treatment of pathologies in which a ?-amyloid peptide (?-A4) formation inhibitor provides a therapeutic benefit. Particular such pathologies are senile dementia, Alzheimer's disease, Down's syndrome, Parkinson's disease, amyloid angiopathy, cerebrovascular disorders, frontotemporal dementias and Pick's disease, post-traumatic dementias, pathologies linked to neuroinflammatory processes, Huntington's disease and Korsakov's syndrome.
Type:
Grant
Filed:
March 20, 2008
Date of Patent:
July 20, 2010
Assignee:
Sanofi-Aventis
Inventors:
Sylvie Baltzer, Marc Pascal, Viviane Van Dorsselaer
Abstract: The invention concerns compounds of general formula (I), wherein n, X1, X2, X3, X4, Y and W are as defined herein. The invention also concerns a method for preparing said compounds and their therapeutic use.
Type:
Grant
Filed:
January 8, 2008
Date of Patent:
June 29, 2010
Assignee:
Sanofi-Aventis
Inventors:
Laurent Dubois, Yannick Evanno, Andre Malanda
Abstract: A method of treating or preventing Alzheimer's disease, Parkinson's Disease and/or schizophrenia, this method comprising administering to a patient in need of such treatment a compound of formula: in which R, R3 and R4 are as defined in the specification.
Type:
Grant
Filed:
November 12, 2004
Date of Patent:
June 22, 2010
Assignee:
Aventis Pharma S.A.
Inventors:
Daniel Achard, Herve Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.
Type:
Grant
Filed:
November 29, 2007
Date of Patent:
June 22, 2010
Assignee:
Aventis Pharmaceuticals Inc.
Inventors:
Patrick Shum, Alexandre Gross, Liang Ma, Daniel G. McGarry, Gregory H. Merriman, David Rampe, Garth Ringheim, Jeffrey Stephen Sabol, Francis A. Volz
Abstract: The invention therefore relates to compounds of the formula I in which the variables are as defined in the specification, to pharmaceutical compositions containing them and to their use for therapeutically lowering blood glucose levels.
Abstract: The invention relates to compounds of formula (I), wherein X, R1, R2, R3, R4 and R5 are as described herein. The invention also includes preparative methods for the preparation of compounds of formula (I). A method for the therapeutic use of the inventive compounds is also disclosed and claimed.
Type:
Grant
Filed:
May 14, 2008
Date of Patent:
June 22, 2010
Assignee:
Sanofi-Aventis
Inventors:
Francis Barth, Claude Vernhet, Murielle Rinaldi-Carmona, CaroleElisabeth Guillaumont-Legeay
Abstract: The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally an isotonicizing agent, buffers or further excipients or combinations thereof, the pharmaceutical formulation having a pH in the acidic range.
Abstract: The invention relates to a compound having general formula (I): Wherein n, A, R1, R2, and R3 are as defined herein. The invention also relates to methods of preparation of compound of formula (I) as well as its use in therapeutics.
Type:
Grant
Filed:
March 31, 2006
Date of Patent:
April 13, 2010
Assignee:
Sanofi-Aventis
Inventors:
Ahmed Abouabdellah, Antonio Almario Garcia
Abstract: The present invention relates to a novel method for the preparation of azetidine derivatives such as N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-quinol-6-ylmethylsulfonamide and the dihydrochloride thereof and N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.
Type:
Grant
Filed:
March 22, 2007
Date of Patent:
March 30, 2010
Assignee:
Aventis Pharma SA
Inventors:
Stephane Mutti, Michel Lavigne, Luc Grondard, Joel Malpart, Joerg Rieke-Zapp, Veronique Crocq-Stuerga
Abstract: The invention relates to a compound having general formula (I): Wherein m, R1 and R2 are as defined herein. The invention also relates to the use of the compound in therapeutics. More specifically, the compounds of the invention are inhibitors of the FAAH enzyme, and therefore, can be used for the treatment of various disorders associated with FAAH enzyme, which include in a non-limiting manner, pain, eating disorders, neurological and psychiatric pathologies, among other disorders.
Type:
Grant
Filed:
June 22, 2006
Date of Patent:
March 30, 2010
Assignee:
Sanofi-Aventis
Inventors:
Ahmed Abouabdellah, Antonio Almario Garcia, Christian Hoornaert, Adrien Tak Li
Abstract: The subject of the present invention is compounds corresponding to formula (I): Wherein X, R1, R2, R3 and R4 are as described herein. The invention also relates to a method for the preparation and application of said compounds as cannabinoid CB1 receptor antagonists.
Type:
Grant
Filed:
August 1, 2007
Date of Patent:
March 30, 2010
Assignee:
Sanofi-Aventis
Inventors:
Jean-Philippe Ducoux, Francis Barth, Murielle Rinaldi-Carmona, Christian Congy
Abstract: The present invention relates to certain esters of substituted 3-aminopropane phosphinic acid derivatives of formula I: wherein R, R1 and R2 are as defined herein. The compounds of this invention are useful in treating a variety of diseases including but not limited to depression, anxiety, certain psychiatric symptoms, cognitive impairment and schizophrenia.
Type:
Grant
Filed:
July 10, 2007
Date of Patent:
March 30, 2010
Assignee:
Aventis Pharmaceuticals Inc.
Inventors:
Alan John Collis, Gregory Bernard Poli, Yong Mi Choi-Sledeski
Abstract: The invention concerns a compound of formula (I): Wherein A, l, m, n, R1 and R2 are as defined herein. The compounds of this invention are useful as medicaments, particularly, in the treatment of disorders improved by modulation of the histamine H3 receptor.
Type:
Grant
Filed:
May 19, 2008
Date of Patent:
March 16, 2010
Assignee:
sanofi-aventis
Inventors:
Juan Antonio Diaz Martin, Beatriz Escribano Arenales, Maria Dolores Jimenez Bargueno
Abstract: The invention relates to a compound of formula (I): Wherein m, n, X, Y, R1, R2, R3 and R4 are as defined herein. The invention also relates to the use of same in therapeutics.
Type:
Grant
Filed:
August 21, 2008
Date of Patent:
March 9, 2010
Assignee:
Sanofi-Aventis
Inventors:
Ahmed Abouabdellah, Antonio Almario Garcia, Jacques Froissant, Christian Hoornaert